Literature DB >> 10489624

Skin precancer.

D E Brash1, J Pontén.   

Abstract

Squamous cell carcinoma of the skin and melanoma are the rare progeny of precancerous lesions that usually remain stable or regress. For SCC the sequence appears to include TP53 mutant clones in normal skin; dysplasia; carcinoma in situ; and SCC. When such lesions are contiguous, their TP53 mutations are consistent with a single clonal lineage. The set of TP53 mutations in tumours is more restricted than in precancers, suggesting additional selection. Melanoma lies at the end of a continuum including mole, dysplastic naevus, radial growth melanoma and vertical growth. The genetics of melanoma is less clear. Basal cell carcinomas seem to arise without a precancer and contain mutations in TP53 and PTCH. Childhood sunlight exposure directs the location and frequency of precancers. For melanoma, its effects on intermittently exposed body sites are superimposed on the effect at sites chronically exposed. SCC precancers and tumours, BCC tumours and melanoma cell lines contain UV induced mutations. Sun exposed skin of normal individuals contains thousands of small clones of TP53 mutated cells. Predisposition to sunlight induced precancer is a multigenic trait involving factors such as hair and skin color, DNA repair proficiency and mole type and number. These each contribute a relative risk on the order of two to four. Familial predisposition to dysplastic naevi carries a larger risk. The cell of origin for melanoma is uncontroversial, and the proposed hair follicle origin of BCC is consistent with the presence of stem cells in the bulge region. The origin of SCCs and the arrangement of interfollicular stem cell compartments are less clear. Clonal expansion of the initial mutated cell may also be driven by sunlight. When a mutation confers apoptosis resistance, as TP53 mutations do, subsequent UV exposure will be more likely to kill normal cells than mutants. The latter can expand into a clone, only one cell of which need be mutated again. Immunosuppressant drugs may have the same effect as UV, facilitating the clonal expansion of precancers. In the absence of exogenous influences, mutant clones and precancers tend to regress. There is little evidence that regression of precancers is immunological, though regression of melanoma appears to be. The chemotherapeutic agent 5-FU causes regression of dysplasias by removing initiated cells, perhaps by enhancing apoptosis. In contrast, retinoic acid temporarily suppresses clonal expansion. Most sunscreens are mutagenic, with as yet unknown consequences. Mice develop dysplasias and SCCs after UV irradiation. Initiation and clonal expansion of dysplasias is UV driven, but conversion to SCC and subsequent growth involve spontaneous events. With chemical carcinogens mice develop papillomas that usually regress and thus are precancers. Tumour promotion yields abundant low risk papillomas that contain Hras1 mutations but rarely progress to SCC. High risk papillomas are infrequent but do convert to SCC, particularly if re-treated with mutagens. Conversion to SCC is associated with TP53 mutations. The mechanisms of multiple mutation and clonal expansion observed in human and mouse systems, respectively, are beginning to converge into a coherent understanding of precancerous events in skin.

Entities:  

Mesh:

Year:  1998        PMID: 10489624

Source DB:  PubMed          Journal:  Cancer Surv        ISSN: 0261-2429


  13 in total

1.  Metakaryotic stem cell lineages in organogenesis of humans and other metazoans.

Authors:  Elena V Gostjeva; Vera Koledova; Aoy Tomita-Mitchell; Michael Mitchell; Mary A Goetsch; Susannah Varmuza; Janna N Fomina; Firouz Darroudi; William G Thilly
Journal:  Organogenesis       Date:  2009-10       Impact factor: 2.500

2.  Distribution of conjunctival ultraviolet autofluorescence in a population-based study: the Norfolk Island Eye Study.

Authors:  J C Sherwin; A W Hewitt; L S Kearns; M T Coroneo; L R Griffiths; D A Mackey
Journal:  Eye (Lond)       Date:  2011-04-15       Impact factor: 3.775

3.  Beta-arrestin2 functions as a phosphorylation-regulated suppressor of UV-induced NF-kappaB activation.

Authors:  Bing Luan; Zhenning Zhang; Yalan Wu; Jiuhong Kang; Gang Pei
Journal:  EMBO J       Date:  2005-11-24       Impact factor: 11.598

Review 4.  Keratinocyte stem cells and the targets for nonmelanoma skin cancer.

Authors:  Ashok Singh; Heuijoon Park; Thaned Kangsamaksin; Anupama Singh; Nyssa Readio; Rebecca J Morris
Journal:  Photochem Photobiol       Date:  2012-01-31       Impact factor: 3.421

5.  High incidence of epithelial cancers in mice deficient for DNA polymerase delta proofreading.

Authors:  Robert E Goldsby; Laura E Hays; Xin Chen; Elise A Olmsted; William B Slayton; Gerry J Spangrude; Bradley D Preston
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-12       Impact factor: 11.205

6.  A definitive role of ornithine decarboxylase in photocarcinogenesis.

Authors:  N Ahmad; A C Gilliam; S K Katiyar; T G O'Brien; H Mukhtar
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

7.  Induction of KLF4 in basal keratinocytes blocks the proliferation-differentiation switch and initiates squamous epithelial dysplasia.

Authors:  K Wade Foster; Zhaoli Liu; Clinton D Nail; Xingnan Li; Thomas J Fitzgerald; Sarah K Bailey; Andra R Frost; Iuri D Louro; Tim M Townes; Andrew J Paterson; Jeffrey E Kudlow; Susan M Lobo-Ruppert; J Michael Ruppert
Journal:  Oncogene       Date:  2005-02-24       Impact factor: 9.867

8.  Optical coherence tomography quantifying photo aging: skin microvasculature depth, epidermal thickness and UV exposure.

Authors:  Jonas Olsen; Giovanni Gaetti; Kasper Grandahl; Gregor Borut Ernst Jemec
Journal:  Arch Dermatol Res       Date:  2021-06-10       Impact factor: 3.017

Review 9.  Early cancers of the skin: clinical, histopathological, and molecular characteristics.

Authors:  Minoru Takata; Toshiaki Saida
Journal:  Int J Clin Oncol       Date:  2005-12       Impact factor: 3.850

10.  Quantitative approach to skin field cancerization using a nanoencapsulated photodynamic therapy agent: a pilot study.

Authors:  Simone K Passos; Paulo En de Souza; Priscila Kp Soares; Danglades Rm Eid; Fernando L Primo; Antonio Cláudio Tedesco; Zulmira Gm Lacava; Paulo C Morais
Journal:  Clin Cosmet Investig Dermatol       Date:  2013-02-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.